Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
Programmable RNA delivery platform targeting non-hepatic tissues
Sixfold Bioscience is a biotechnology company developing a programmable RNA-based delivery platform that exploits the body's natural extracellular RNA transport pathways to direct therapeutic RNA molecules to specific non-hepatic tissues and cell types. The platform uses computationally designed chemical modifications…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
Global CDMO for biologics development and manufacture
Lonza is one of the world's largest contract development and manufacturing organisations, providing services across biologics, cell and gene therapy, and small molecules. Its primary UK site in Slough is a multi-product cGMP facility specialising in mammalian biopharmaceutical development and manufacture. The…
Automated cell culture systems and CDMO for cell therapy manufacturing
Mytos is a biotechnology company developing automated cell culture systems for pharmaceutical and biotechnology customers, replacing manual T-flask culture with closed, robotic instrumentation to improve reproducibility and scalability of human cell production. The platform serves drug discovery and clinical-stage…
Programmable iPSC cell therapies for cancer and autoimmunity
Xap Therapeutics is a Cambridge-based biotechnology company developing a synthetic biology platform for next-generation cell therapeutics. The company applies CRISPR technology to engineer induced pluripotent stem cells (iPSCs) into a universal "chassis" cell that can be functionalised with engineered receptors and…
AI-driven AAV capsid engineering for next-generation gene therapy
Lir Therapeutics is an early-stage biotechnology company redesigning adeno-associated virus capsids for gene therapy using an AI-first platform. Its platform integrates high-throughput experimental data generation with machine learning models trained on structural, functional and immunogenicity representations of…
Targeted nanoparticle formulations for nucleic acid delivery
XapHe is a biotechnology company developing peptide-based nanoparticles for therapeutic nucleic acid delivery. Its HAWC platform packages RNA and DNA payloads into formulations designed for cell entry and tissue targeting. The company supplies transfection kits and offers custom nanoparticle formulation services for…
Standardised mesenchymal stromal cell therapies for chronic tissue repair
TrophiCell develops cell therapies based on mesenchymal stromal cells, which release signals involved in tissue repair and immune regulation. Its patented production method aims to generate standardised cells at scale from a single donor, addressing variability associated with earlier cell therapy approaches. The…
Light-controlled droplet microfluidics for single-cell functional analysis
Lightcast Discovery is a life science tools company developing a droplet-based system for single-cell functional analysis. Using light to precisely control picolitre-scale droplets, the platform enables parallel interrogation of tens of thousands of individual cells across a range of functional assays, including…
Cell-free enzymatic DNA manufacturing for genetic medicines
Touchlight is a contract development and manufacturing organisation producing synthetic DNA for genetic medicine applications using a cell-free enzymatic process. Its linear, covalently closed DNA constructs are free from bacterial sequences and antibiotic resistance genes, offering regulatory and safety advantages…
Early phase clinical trial CRO based at London Bridge
Richmond Pharmacology is a contract research organisation specialising in early phase and first-in-human clinical trials for pharmaceutical and biotech companies. Operating from hospital-adjacent facilities at London Bridge and St George's University London, the company has conducted over 20% of all UK Phase I studies…
Cell therapy for vascular regeneration in ischaemic and wound healing conditions
VascVersa is a Belfast-based regenerative medicine company developing cell therapies for vascular regeneration and repair. The company's technology uses vasoreparative cells to stimulate new blood vessel formation and restore blood supply in conditions characterised by impaired circulation. The lead programme targets…
Synthetic gene promoter platform for biologics and cell and gene therapy
SynGenSys is a synthetic biology company developing proprietary libraries of synthetic gene promoters and signal peptides designed to improve the yield, specificity, and reliability of recombinant protein expression. Its computational platform uses bioinformatics and AI to design novel promoters from first principles,…
Epigenetic reprogramming and senolytic therapeutics for cancer and ageing
199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease. Its lead programme applies partial cellular reprogramming to modify the behaviour of glioblastoma cells, reducing malignancy and reactivating natural…
Personalised T cell therapy platform for solid tumour treatment
Swarm Oncology is a pre-clinical biotechnology company developing personalised T cell therapies for advanced solid cancers. Its platform combines in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with tumour-homing phenotypes, addressing a key…
Human iPSC-based safety and genotoxicity testing for gene therapy vectors
TestAVec is a provider of in vitro safety testing services for gene therapy and viral vector products, serving academic researchers and industry developers. The company's human stem cell based platform assesses vector-induced genotoxicity, evaluates patients' DNA repair capacity ahead of radiation or chemotherapy, and…
Mitochondrial transplantation platform to restore cellular energy and regeneration
Recondria Therapeutics is a developer of a mitochondrial transplantation platform designed to restore cellular energy, accelerate tissue recovery and support regenerative medicine. The company's approach involves isolating healthy mitochondria and delivering them to damaged cells to restore ATP production and cellular…
Contract packing, storage and logistics for pharmaceutical and cell therapy
Central Pharma provides pharmaceutical contract packing, regulated storage and specialist supply chain services. Its capabilities include GMP filling and packing, serialisation, regulatory support and temperature-controlled logistics. For cell and gene therapy developers, it offers cleanroom kitting and storage…
GMP lentiviral and retroviral vector design and manufacture for CGT
ViroCell Biologics is a specialist contract development and manufacturing organisation providing GMP design and manufacture of lentiviral and retroviral vectors for cell and gene therapy clinical trials. The company serves academic and corporate innovators developing CAR-T therapies, rare disease gene therapies, and…
Single-cell cloning and clonal assurance platforms for biomanufacturing
Advanced Instruments is a life science instrumentation company whose Solentim portfolio supports cell line development for biopharmaceutical manufacturing. Its systems combine single-cell deposition, automated imaging and AI-assisted clonality assessment. Associated growth supplements and data-management software…